BIIB 100
Alternative Names: BIIB-100; KPT 350Latest Information Update: 20 Mar 2025
At a glance
- Originator Karyopharm Therapeutics
- Class Anti-inflammatories; Antiepileptic drugs; Antirheumatics; Fluorinated hydrocarbons; Hydrazines; Neuroprotectants; Small molecules; Triazoles
- Mechanism of Action Exportin 1 protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes - Amyotrophic lateral sclerosis
Highest Development Phases
- Phase I Amyotrophic lateral sclerosis
- Preclinical Unspecified
- Discontinued Brain injuries; Duchenne muscular dystrophy; Epilepsy; Multiple sclerosis; Rheumatoid arthritis; Systemic lupus erythematosus
Most Recent Events
- 31 Dec 2024 Preclinical trials in Unspecified in USA (PO)
- 29 Feb 2024 KPT 350 is still in phase I trials for Amyotrophic lateral sclerosis in USA (KARYOPHARM THERAPEUTICS SEC filing, Form 10-K, March 2024)
- 29 Feb 2024 BIIB 100 is available for licensing as of 22 Mar 2024. https://www.sec.gov/ixviewer/ix.html?doc=/Archives/edgar/data/1503802/000095017024022650/kpti-20231231.htm